Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than immunotherapy treatments.
Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC patients may be better served staying on targeted therapies rather than immunotherapy treatments.